Time to Treatment Discontinuation and Cost Effectiveness of Third-Line Therapies in Advanced Colorectal Cancer: Real-World Evidence from the NIH All of Us Research Program - Quiz - MDSpire

Time to Treatment Discontinuation and Cost Effectiveness of Third-Line Therapies in Advanced Colorectal Cancer: Real-World Evidence from the NIH All of Us Research Program

  • By

  • Patrick J. Kiel

  • Mark W. McGiffin

  • Todd C. Skaar

  • Michael A. Preston

  • March 10, 2026

  • 0 min

Share

Original Source(s)

Time to Treatment Discontinuation and Cost Effectiveness of Third-Line Therapies in Advanced Colorectal Cancer: Real-World Evidence from the NIH All of Us Research Program

  • by Patrick J. Kiel, Mark W. McGiffin, Todd C. Skaar, Michael A. Preston

  • March 10, 2026

Related Content

Worldwide Impact of Colorectal Cancer in 2022 and Forecasts for 2050: Incidence and Mortality Data from GLOBOCAN

Investigation of Euphorbia Lathyris L. Seed's Mechanisms in Colorectal Cancer Treatment Through Network Pharmacology and Molecular Docking Approaches

Barriers and Variations in Cancer Diagnosis: A Cross-Sectional Analysis of Patient Journeys and Healthcare Provider Timelines in Public Health Systems of Chile, Colombia, and Ecuador